Detection of N-Ras codon 61 mutations in subpopulations of tumor cells in multiple myeloma at presentation
Open Access
- 1 September 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 98 (5) , 1555-1560
- https://doi.org/10.1182/blood.v98.5.1555
Abstract
Activating point mutations in codons 12, 13, or 61 of the K-ras and N-ras genes have been reported to occur in up to 40% of patients with multiple myeloma at presentation. In a study of 34 presentation myeloma cases using a sensitive polymerase chain reaction-restriction fragment length polymorphism strategy on enriched tumor cell populations, the present study detected N-ras codon 61 mutation-positive cells in all patients. Quantitative plaque hybridization using allele-specific oligonucleotide probes showed that in the majority of patients, ras mutation-positive cells comprise only a subpopulation of the total malignant plasma cell compartment (range, 12%-100%). Using clonospecific point mutations in the 5′ untranslated region of the BCL6 gene to quantitate clonal B cells in FACS-sorted bone marrow populations from 2 patients, the representation of ras mutation-positive cells was independent of immunophenotype. These observations imply that mutational activation of N-ras codon 61 is a mandatory event in the pathogenesis of multiple myeloma; such mutations provide a marker of intraclonal heterogeneity that may originate at an earlier ontologic stage than immunophenotypic diversification of the malignant B cell clone.Keywords
This publication has 20 references indexed in Scilit:
- Frequent Dysregulation of the c-maf Proto-Oncogene at 16q23 by Translocation to an Ig Locus in Multiple MyelomaBlood, 1998
- Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3Nature Genetics, 1997
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996
- 2Biological aspects of multiple myelomaBailliere's Clinical Haematology, 1995
- Who benefits from high-dose therapy for multiple myeloma?Journal of Clinical Oncology, 1995
- Cell Surface Markers in Multiple MyelomaMayo Clinic Proceedings, 1994
- N- and K-Ras Oncogenes in Plasma Cell DyscrasiasLeukemia & Lymphoma, 1994
- Mutational activation of N- and K-ras oncogenes in plasma cell dyscrasiasBlood, 1993
- Immunophenotypic heterogeneity of multiple myeloma: influence on the biology and clinical course of the diseaseBritish Journal of Haematology, 1991
- Ras oncogene mutation in multiple myeloma.The Journal of Experimental Medicine, 1989